Report Categories
View AllRecent Articles
View All
WRD WeRide shares gain 321 percent despite reporting a wider than expected Q4 2025 loss
How DarkIris DKI guidance shapes future expectations
Vertex Pharmaceuticals VRTX FDA ALYFTREK Label Expansion Reinforces Core Cystic Fibrosis Franchise Amid Broader Pipeline Diversification Push
ALLE Allegion posts 42 percent Q4 2025 EPS miss with shares dipping 09 percent in daily trading